Intervention: Cyclosporine
Trial phase: Phase 4
ATC code: L04AD01 | S01XA18
SMILES: CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Twice-daily applications of dapsone gel to one-half of the face. Dapsone facial gel was applied twice daily to one side of the face of all subjects in this group in a split-face model. On weekdays during the two-week trial, the investigator scored Erythema on a scale of 0 (none) to 8 (severe) and Dryness on a scale of 0 (none) to 8 (severe).
Eligibility criteria:
Inclusion Criteria:

Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed.
Male and female subjects aged from 18 to 45 years at time of consent.
Has a Fitzpatrick Skin Type of I, II, or III.
Is willing to discontinue use of all facial products (other than the cleanser provided and makeup or razor and facial shave product) on the face for the 3 days before their baseline/day 0 visit and use only the provided facial products and their normal makeup or razor and facial shaving product for the duration of the study.
Is willing to not change brands of makeup or razor and facial shave product during the study.
Is willing to refrain from using any facial product on the face other than study products and their normal makeup or razor and facial shave product for the duration of the study.
Is willing to refrain from exercising prior to their instrument appointments.
Is willing to refrain from showering or drinking caffeinated beverages within 1 hour prior to their instrument visits.
Is willing to report to the site for each visit with a clean face and no makeup.
Is willing to avoid sunburn, tanning, tanning beds or other excessive sun exposure. Understands that if their skin tone changes significantly during the study it will be necessary to discontinue their participation.
Able to complete the study and to comply with study instructions.
Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.

Exclusion Criteria:

Female subjects who are pregnant, trying to become pregnant, or breast feeding.
Male subjects that have facial beards (mustache and/or goatee is acceptable).
Is a Type I diabetic.
Has active or chronic skin allergies.
Has a history of acute or chronic disease that might interfere with, or increase the risk of study participation.
Has participated in other facial studies in the preceding 30 days or other clinical studies in preceding 14 days.
Had skin cancer treatment in preceding 12 months.
Has damaged skin on facial areas (eg, from sunburn, tattoos, scars).
Had any medical procedure (e.g., laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months.
Had any cosmetic procedure (e.g., microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit.
Use of topical retinoids or related agents for the treatment of acne or photoaging in the preceding 6 months.
Live in the same household as currently enrolled subjects.
Employees of investigator/clinical research organization (CRO) or Stiefel Laboratories involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.
Any other condition or factor the investigator or his duly assigned representative believes may affect the skin response or the interpretation of the test results.